Bio Pharma Dive

JULY 10, 2023

The licensing agreement for the biotech’s viral vector platform follows recent Astellas agreements with Taysha Gene Therapies and Kate Therapeutics.

Gene Therapy 215

Gene Therapy Gene Licensing Licensing 215

Bio Pharma Dive

APRIL 28, 2022

Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing agreements on its last two pipeline programs.

Gene Therapy 263

Gene Therapy Gene Sales Licensing 263

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Pharmaceutical Technology

JUNE 19, 2023

Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market. Laurus Labs CEO Satyanarayana Chava stated: “This collaboration exhibits our commitment towards the cell and gene therapy (CGT) space.

Gene Therapy 246

Gene Therapy Gene Production Pharma Companies 246

Pharmaceutical Technology

JUNE 13, 2023

Beacon Therapeutics has kickstarted its entry into the gene therapy field with a $120m Series A financing. Amongst it was AGTC’s lead clinical candidate, AFTC-501, an adeno-associated virus (AAV) gene therapy for XLRP. Beacon Therapeutics is the third gene therapy company Syncona has launched.

Gene Therapy 246

Gene Therapy Gene Trials Clinical Trials 246

Pharmaceutical Technology

DECEMBER 8, 2022

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies. By Cytiva Thematic.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

Pharmaceutical Technology

MAY 30, 2023

Amplo Biotechnology has received a fast track phase I/II STTR grant from the NIH-NIAMS [National Institutes of Health’s National Institute of Arthritis and Musculoskeletal and Skin Diseases] for its gene therapy AMP-201. The company will receive substantial funding to advance AAV-ColQ gene therapy.

Gene Therapy 244

Gene Therapy Gene Development Clinical Trials 244

Bio Pharma Dive

DECEMBER 2, 2020

The pharma licensed a treatment for a severe type of age-related vision loss, building on past deals that gave it a foothold in gene therapy.

Gene Therapy 251

Gene Therapy Gene Licensing Licensing 251

Bio Pharma Dive

MAY 15, 2023

The Dutch biotech sold a portion of royalties owed by CSL Behring on sales of Hemgenix, adding to a cash pile it has built since out-licensing the treatment.

Gene Therapy 294

Gene Therapy Gene Licensing Licensing 294

Bio Pharma Dive

MARCH 2, 2022

A federal patent board ruled Broad Institute scientists were first to a key gene editing advance, weakening the patent position of Intellia and CRISPR Therapeutics, which hold licenses through the University of California.

Gene Editing 194

Gene Editing Gene Licensing Licensing 194

Pharmaceutical Technology

AUGUST 25, 2022

The European Commission (EC) has granted conditional marketing authorisation (CMA) for BioMarin Pharmaceutical ’s gene therapy, Roctavian (valoctocogene roxaparvovec), to treat adults with severe haemophilia A (congenital Factor VIII deficiency). Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 264

Gene Therapy Gene Clinical Trials Clinical Trials 264

BioSpace

SEPTEMBER 13, 2023

AlveoGene has licensed the U.K. Respiratory Gene Therapy Consortium’s InGenuiTy platform for all uses excluding the CTFR gene, which is already licensed to Boehringer Ingelheim for cystic fibrosis.

Gene Therapy 103

Gene Therapy Gene Licensing Licensing 103

BioSpace

OCTOBER 20, 2022

Kite Pharma entered into a global licensing deal with Refuge Biotechnologies to leverage the latter's propriety gene expression plaform and develop potential blood cancer therapies.

Gene Expression 71

Gene Expression Licensing Licensing Gene 71

Pharmaceutical Technology

JANUARY 5, 2023

Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. By Cytiva Thematic.

Gene Therapy 237

Gene Therapy Gene Development Engineer 237

Pharmaceutical Technology

MAY 24, 2023

It can correct several disease elements associated with PKD, a rare, monogenic red blood cell disorder caused by a mutation in the PKLR gene. It can correct several disease elements associated with PKD, a rare, monogenic red blood cell disorder caused by a mutation in the PKLR gene.

Gene Therapy 130

Gene Therapy Gene Licensing Licensing 130

Worldwide Clinical Trials

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow.

Gene Editing 190

Gene Editing Gene Gene Therapy In-Vivo 190

Bio Pharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Gene Editing 281

Gene Editing Insulin Gene Licensing 281

pharmaphorum

JANUARY 2, 2024

Novartis has doubled down on its gene therapy collaboration with Voyager Therapeutics, licensing candidates for Huntington's disease and SMA

Gene Therapy 88

Gene Therapy Gene Licensing Licensing 88

Pharmaceutical Technology

NOVEMBER 9, 2022

On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies. An approval decision on the gene therapy, also known as EtranaDez, is expected by the end of this month. million price tag.

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

Bio Pharma Dive

JANUARY 31, 2023

For $10 million up front, UniQure has licensed rights to its second experimental treatment for the condition, a medicine from startup Apic Bio that should enter human testing later this year.

Gene Therapy 210

Gene Therapy Gene Licensing Licensing 210

BioSpace

OCTOBER 11, 2021

Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day.

Licensing 92

Licensing Licensing Gene Therapy Gene 92

Pharmaceutical Technology

APRIL 13, 2023

ImaginAb will be responsible for licensing and supplying the clinical doses of 89Zr crefmirlimab berdoxam, its investigational CD8 ImmunoPET tracer, to Leucid Bio. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Licensing 130

Licensing Licensing Gene Therapy Gene 130

Pharmaceutical Technology

JUNE 27, 2023

The FDA has accepted a biologics license application (BLA) for Pfizer's fidanacogene elaparvovec to treat adults with haemophilia B.

Gene Therapy 240

Gene Therapy Licensing Licensing Gene 240

Pharmaceutical Technology

DECEMBER 14, 2022

Merck and Synplogen have signed a non-binding Memorandum of Understanding (MoU) to expedite the development and manufacturing of viral vector-based gene therapy applications. The firms intend to merge their expertise to provide simplified viral vector gene therapy development, production and testing in Japan. By Cytiva Thematic.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

Bio Pharma Dive

JANUARY 19, 2023

Shoreline will acquire a preclinical NK cell therapy Editas has been developing, as well as a license to use the CRISPR biotech’s gene editing technology.

Gene Editing 256

Gene Editing Licensing Licensing Gene 256

XTalks

JANUARY 3, 2024

Novartis and Voyager Therapeutics have struck a licensing deal that will see Novartis pay Voyager $100 million upfront to develop gene therapy candidates targeting Huntington’s disease (HD) and spinal muscular atrophy (SMA). The total value of the deal could potentially reach $1.2 Sandrock, Jr., MD, PhD, CEO of Voyager.

Gene Therapy 52

Gene Therapy Gene Licensing Licensing 52

BioPharma Reporter

APRIL 24, 2023

bluebird bio has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD).

Gene Therapy 93

Gene Therapy Gene Licensing Licensing 93

Fierce Pharma

SEPTEMBER 14, 2023

Otsuka teamed up with Shape Therapeutics in an eye disease gene therapy deal potentially worth $1.5 Otsuka teamed up with Shape Therapeutics in an eye disease gene therapy deal potentially worth $1.5 Insilico Medicine out-licensed an AI-discovered cancer drug candidate to Exelixis.

Gene Therapy 87

Gene Therapy Gene Licensing Licensing 87

Pharmaceutical Technology

APRIL 13, 2023

Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). Also known as lovo-cel, bluebird bio’s product is a lentiviral gene therapy.

Gene Therapy 147

Gene Therapy Gene FDA Approval Licensing 147

Bio Pharma Dive

DECEMBER 14, 2021

Fitusiran, which Sanofi licensed from Alnylam, could finally get to market after trial delays and safety concerns slowed its progress. But gene therapies and other new medicines might provide competition.

Gene Therapy 317

Gene Therapy Licensing Licensing Gene 317

Drug Discovery World

NOVEMBER 16, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the world’s first gene therapy for sickle-cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). Casgevy is designed to work by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin.

Gene Therapy 111

Gene Therapy Gene Gene Editing Clinical Trials 111

BioTech 365

JUNE 30, 2021

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement License agreement to enhance Nippon Gene’s CRISPR/Cas9 research reagents offering DUBLIN & TOKYO–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad … Continue reading →

Genome 52

Genome Genomics Licensing Licensing 52

Pharmaceutical Technology

OCTOBER 14, 2022

Pharmaceutical companies Xcell Biosciences (Xcellbio) and aCGT Vector have partnered to expedite the development of cell and gene therapies. The two companies will aim to improve the manufacturing and analytic procedures used to develop personalised cell and gene therapies to treat cancer patients.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

BioTech 365

MARCH 2, 2021

ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical License to Nobel prize winning CRISPR technology supports internal research and development DUBLIN, Ireland–(BUSINESS WIRE)–ERS Genomics Limited, which was formed … Continue reading (..)

Gene Editing 52

Gene Editing Genome Genomics Licensing 52

BioTech 365

MAY 6, 2021

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise Newly licensed technologies include use of Genprex’s … Continue reading → (..)

Gene Therapy 52

Gene Therapy Licensing Licensing Gene 52

BioTech 365

JANUARY 19, 2022

Eikonoklastes Bolsters Pipeline, Announces a License for Novel Gene Therapy to Address Neurodegenerative Diseases Eikonoklastes Bolsters Pipeline, Announces a License for Novel Gene Therapy to Address Neurodegenerative Diseases Biopharmaceutical company to develop therapies to address ALS, Alzheimer’s, Parkinson’s and others … Continue reading (..)

Gene Therapy 52

Gene Therapy Licensing Licensing Gene 52

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Gene Therapy 52

Gene Therapy Licensing Licensing Gene 52